Craif is a biotechnology company that utilizes a microRNA database and machine learning algorithms to develop a high-precision cancer risk assessment tool, MySignal®, which analyzes urine and saliva samples for early detection of pancreatic cancer. By collaborating with approximately 30 university hospitals and cancer research centers, Craif aims to enhance early diagnosis and prevention of cancer, thereby reducing the risk of late-stage diagnosis and associated mortality.
Funding
$21.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early detection of pancreatic cancer is challenging due to the lack of effective screening methods, leading to late-stage diagnoses and poor patient outcomes. Traditional diagnostic approaches often involve invasive procedures and may not be suitable for routine screening. This results in delayed treatment and reduced survival rates for individuals at risk.
Solution
Craif offers MySignal®, a high-precision cancer risk assessment tool that utilizes a microRNA database and machine learning algorithms to analyze urine and saliva samples for early detection of cancer. By identifying specific microRNA signatures associated with pancreatic cancer, MySignal® provides a non-invasive method for assessing an individual's risk. The test is developed in collaboration with approximately 30 university hospitals and cancer research centers. The goal is to enhance early diagnosis and prevention of cancer, thereby reducing the risk of late-stage diagnosis and associated mortality.
Target Audience
The primary target audience includes individuals at risk of pancreatic cancer, healthcare providers seeking early detection tools, and corporations looking to support employee health through early cancer screening programs.
Features
- Non-invasive cancer risk assessment using urine and saliva samples
- MicroRNA database and machine learning algorithms for high-precision analysis
- Early detection of pancreatic cancer through specific microRNA signatures
- Collaboration with approximately 30 university hospitals and cancer research centers
- NANO IP® (NANO Intelligence Platform) for effective capture, measurement, analysis, and database creation of nanobiomarkers